GH

Guardant Health, Inc.

NasdaqGSUSDEQUITY DELAYED

170.65

▲ 2.77 (1.65%)

MARKET · —

Price

Open

168.50

Prev close

167.88

Day high

170.83

Day low

165.01

Volume

1.91M

Market cap

—

P/E (TTM)

—

52W range

53.40 – 176.58

Trailing performance

Price return · vs SPY

Returnvs SPY

+8.57% +9.9%

+13.64% +9.9%

+44.64% +41.5%

+65.56% +54.5%

YTD

+67.11% +54.8%

+191.78% +171.8%

+385.47% +311.3%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

163.79

+4.19% from price

SMA 20

159.66

+6.91% from price

SMA 50

153.16

+11.44% from price

SMA 100

127.20

+34.15% from price

SMA 200

114.02

+49.70% from price

EMA 12

163.23

+4.55% from price

EMA 26

159.11

+7.25% from price

EMA 50

150.72

+13.23% from price

RSI (14)

62.5

Neutral

MACD (12,26,9)

4.11

Hist 0.27

ATR (14)

6.92

4.05% of price

Realised vol 30D

45.4%

Annualised

Bollinger upper

175.06

20, 2σ

Bollinger lower

144.27

20, 2σ

50 / 200 cross

Golden

153.16 vs 114.02

Trend bias

Above 200

+49.70%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.92

Less volatile than market

Correlation to SPY

0.20

Largely independent

Realised vol 30D

45.4%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-33.0%

Peak to trough

Max drawdown 5Y

-87.8%

Peak to trough

ATR 14

6.92

4.05% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 170.65

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

GH · links out to the publisher

Palantir, Freeport Clear Buy Points, Lead Five Stocks To Watch Investor's Business Daily · 3h ago Dow Jones Futures Rise After Bearish Market Signal; Bitcoin Keeps Surging Investor's Business Daily · 1d ago Guardant Health (GH) Surges on FDA Approval and Cancer Screening Momentum Insider Monkey · 5d ago Guardant Health Insider Sold Shares Worth $7,645,218, According to a Recent SEC Filing MT Newswires · 8d ago Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate MarketBeat · 8d ago Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead Zacks · 9d ago Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High? Zacks · 10d ago Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million Motley Fool · 10d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.